Blog
RSS FeedPosted by Michael Wonder on 24 Jan 2018
How excluding some benefits from value assessment of new drugs impacts innovation
23 January 2018 - Payers often assess the benefits of new drugs relative to costs for reimbursement purposes, but they frequently ...
Posted by Michael Wonder on 23 Jan 2018
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
23 January 2018 - Although health technology assessment systems base their decision making process either on economic evaluations or comparative clinical ...
Posted by Michael Wonder on 23 Jan 2018
NICE backs Bayer’s Eylea, Novartis’ Lucentis for sight condition
23 January 2018 - Cost regulators for NHS funded therapies in England and Wales have issued updated guidelines for the ...
Posted by Michael Wonder on 22 Jan 2018
Biogen ‘optimistic’ for NHS access to Spinraza
22 January 2018 - Biogen says it is “optimistic” that patients in England and Wales with a rare spinal disorder ...
Posted by Michael Wonder on 21 Jan 2018
A tale of 2 friends with breast cancer; 1 has coverage for costly drug, the other forced to pay
20 January 2018 - Two women say their cases challenge commonly held belief that B.C. is the gold standard for cancer ...
Posted by Michael Wonder on 21 Jan 2018
At $262.40 per pill, the cancer drug that could save her life isn’t covered in B.C.
19 January 2018 - Karen McLaren of Langley has stage four breast cancer, and has been prescribed a drug that could ...
Posted by Michael Wonder on 18 Jan 2018
Early benefit assessments: the 220th dossier evaluation completed at the turn of the year
18 January 2018 - Oncology remains by far the most common indication. ...
Posted by Michael Wonder on 18 Jan 2018
Out of pocket pain – share your experience
18 January 2018 - The thousands of Australians who have faced high out of pocket medical bills now have a ...
Posted by Michael Wonder on 18 Jan 2018
Draft report for the post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis
18 January 2018 - The draft report for the post-market review of the use of biologics in the treatment of severe ...
Posted by Michael Wonder on 17 Jan 2018
Pfizer asked to submit CDF proposal for Xalkori
17 January 2018 - Pfizer’s Xalkori has been turned away by NICE to treat ROS1-positive advanced non-small cell lung cancer. ...
Posted by Michael Wonder on 17 Jan 2018
NICE approves CDF funding for Janssen’s Darzalex
17 January 2018 - NICE is backing NHS use of Janssen’s Darzalex via the Cancer Drugs Fund for some adults ...
Posted by Michael Wonder on 17 Jan 2018
Consumers to be slugged with $200 private health insurance price rises
17 January 2018 - Consumers will be slugged with an average 4% rise in private health insurance premiums this year ...
Posted by Michael Wonder on 16 Jan 2018
How Ottawa's using a fake drug crisis to force through damaging pharmaceutical policy
16 January 2018 - There is no affordability crisis to justify expanding drug price regulation, or a new national government-run pharmacare ...
Posted by Michael Wonder on 16 Jan 2018
In a nutshell 2017: new issue with facts and graphics from the IQWiG
15 January 2018 - Third issue with focus on quality assurance/numerous graphs illustrate work results. ...
Posted by Michael Wonder on 16 Jan 2018
Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: studies of direct comparison are useful
4 January 2018 - Four dossier assessments involving comparisons between immunotherapies and chemotherapies for the same therapeutic indication in 2017/comparison ...